Actuate Therapeutics Reports Significant Survival Improvement in Metastatic Pancreatic Cancer Phase 2 Trial
Key Insights
Actuate Therapeutics (search) presented positive Phase 2 data showing elraglusib combined with gemcitabine/nab-paclitaxel improved median survival from 7.2 to 10.1 months in previously untreated metastatic pancreatic cancer (search) patients.
The company plans to consult with the FDA on next steps toward potential approval by year end following the clinically significant survival improvement demonstrated at ASCO.
Craig-Hallum analyst Albert Lowe raised his price target to $32 and reiterated a "Buy" rating, while the consensus rating sits at "Strong Buy" based on analyst coverage.
Actuate Therapeutics (search) presented compelling Phase 2 trial results at the American Society for Clinical Oncology (ASCO) conference, demonstrating that its investigational drug elraglusib significantly extended survival in patients with previously untreated metastatic pancreatic cancer (search). The combination therapy showed a clinically meaningful improvement in median overall survival compared to standard treatment alone.
Phase 2 Trial Results Show Survival Benefit
The mid-stage trial evaluated elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) versus standard care in metastatic pancreatic cancer (search) patients who had not received prior treatment. Results showed the combination therapy improved median survival from 7.2 months to 10.1 months on average, representing a clinically significant benefit for this difficult-to-treat patient population.
The positive data has prompted Actuate Therapeutics (search) to plan consultations with the FDA regarding next steps toward potential regulatory approval by year end. This timeline suggests the company believes the survival data may support an accelerated pathway to market authorization.
Analyst Response and Market Impact
Following the ASCO presentation, Craig-Hallum analyst Albert Lowe reiterated his "Buy" rating on Actuate Therapeutics (search) stock and raised his price target to $32. His upwardly revised target signals potential for a 200% rally from current levels. According to Barchart, the consensus rating on ACTU shares based on two analysts sits at "Strong Buy."
The positive clinical update has already driven significant investor interest, with Actuate Therapeutics (search) stock currently up more than 75% versus its year-to-date low at the time of the ASCO presentation.
Broader Context at ASCO
The Actuate Therapeutics (search) data was presented alongside other notable developments at ASCO, including Bristol-Myers Squibb (search)'s announcement of an $11 billion partnership with BioNTech. The conference served as a platform for multiple companies to showcase advancing cancer therapeutics, with analysts identifying several stocks as having significant upside potential based on their clinical progress.